FDC LIMITED
Latest filings
- FDC approves Rs 120 crore share buyback at Rs 500 per share · Corporate Actions
- FDC Q2 FY27 revenue rises 21%, profit rises 73%; Rs 120 crore buyback approved · Results
- FDC approves Rs 120 crore buyback of up to 24 lakh shares · Results
Snapshot
What the business is, and whether it's a good one at a fair price.
Manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs), split across three businesses. Domestic Formulations contributed 82% of FY26 sales and sells branded medicines in India, including antibiotics like Zifi, rehydration brand Electral and energy drink Enerzal, through prescriptions and over-the-counter channels. Export Formulations sells generic drugs in overseas markets, primarily the United States, and received US FDA approvals for Fluconazole Tablets and Cefixime for Oral Suspension USP during FY26. The API business manufactures and sells bulk drug ingredients to other pharmaceutical companies. FY26 consolidated revenue was Rs. 2,171 crore with EBITDA margin of 20.2%, and the Q4 FY26 quarter alone brought in Rs. 585 crore at 18.9% year-on-year growth, led by exports. Operating costs are dominated by materials (26.5% of revenue), employee costs (22.2%) and other operating expenses (29.1%), with depreciation at 2.7% and capex at 8.6% of revenue.
Scorecard
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Strengths
Concerns
Charts
How has the market priced it — with filings on the timeline?
FDC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from FDC LIMITED's filed financials and exchange disclosures
What does FDC LIMITED do?
FDC LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol FDC.
Is FDC LIMITED profitable?
Yes. Over the trailing twelve months FDC LIMITED reported a net profit of ₹293 Cr on revenue of ₹2,190 Cr.
Does FDC LIMITED pay a dividend?
Yes. The dividend yield is 1.32% at the current price. It paid out 29% of its profit as dividend in FY26.
Is FDC LIMITED debt-free?
Yes. It reported no borrowings on its 31 Mar 2026 balance sheet, and ₹49 Cr of cash.
Is FDC LIMITED expensive compared with its peers?
On trailing P/E, FDC LIMITED ranks 50 of 158 in Pharmaceuticals — cheaper than 69% of them, against an industry median of 30.8×. This is a position, not a valuation judgement.
How much does the FDC LIMITED share price move in a day?
On a typical session FDC LIMITED moves 1.11% — that is the median absolute close-to-close move across its last 267 trading days. MarketPing measures each filing's price reaction against it.
Where can I track FDC LIMITED's announcements?
Every NSE and BSE filing by FDC LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.